Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

BioScience Health Innovations (BHIC) Shares Outstanding (Weighted Average) (2019 - 2026)

BioScience Health Innovations has reported Shares Outstanding (Weighted Average) over the past 8 years, most recently at $11.4 million for Q1 2026.

  • Quarterly Shares Outstanding (Weighted Average) fell 74.09% to $11.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $11.4 million through Mar 2026, down 74.09% year-over-year, with the annual reading at $11.0 million for FY2025, 4.73% up from the prior year.
  • Shares Outstanding (Weighted Average) was $11.4 million for Q1 2026 at BioScience Health Innovations, up from $11.0 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $43.9 million in Q1 2025 and troughed at $5.5 million in Q1 2022.
  • The 5-year median for Shares Outstanding (Weighted Average) is $11.4 million (2026), against an average of $22.0 million.
  • Year-over-year, Shares Outstanding (Weighted Average) surged 198.57% in 2024 and then crashed 74.09% in 2026.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $5.5 million in 2022, then surged by 518.23% to $33.8 million in 2023, then crashed by 68.95% to $10.5 million in 2024, then rose by 4.73% to $11.0 million in 2025, then grew by 3.62% to $11.4 million in 2026.
  • Per Business Quant, the three most recent readings for BHIC's Shares Outstanding (Weighted Average) are $11.4 million (Q1 2026), $11.0 million (Q4 2025), and $11.0 million (Q3 2025).